Business Context and Reporting Period
Company: Revelation Biosciences, Inc. (REVB)
Reporting Period: Quarter ended September 30, 2024 (Q3 2024)
Business Overview: A clinical-stage biopharmaceutical company developing therapeutics based on its proprietary formulation, Gemini, to harness trained immunity. Key programs include GEM-AKI (acute kidney injury), GEM-CKD (chronic kidney disease), and GEM-PSI (post-surgical infection). The company has no product revenue and relies on capital raises to fund operations.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(2.24) million | $(2.63) million | $(13.31) million | $2.08 million (Income) |
| Operating Expenses | $1.80 million | $2.78 million | $6.22 million | $6.33 million |
| Cash and Equivalents (End of Period) | $6.54 million | $13.99 million | $6.54 million | $13.99 million |
| Stockholders' Equity | $2.67 million | $8.82 million | $2.67 million | $8.82 million |
| Accumulated Deficit | $(38.78) million | $(23.26) million | $(38.78) million | $(23.26) million |
Liquidity: Cash burn for the nine months ended September 30, 2024, was approximately $5.45 million. The company raised approximately $9.16 million in financing activities during the period, primarily through a public offering and warrant inducement exercises.
Material Changes vs. Prior Period
- Net Loss vs. Net Income: The company reported a net loss of $13.31 million for the nine months ended September 30, 2024, compared to net income of $2.08 million in the same period in 2023. The 2023 income was driven by an $8.26 million gain from the change in fair value of warrant liabilities, which was absent in 2024.
- Operating Expenses: Total operating expenses decreased slightly year-over-year for the nine-month period ($6.22 million vs. $6.33 million). Research and Development (R&D) expenses decreased by $0.14 million, while General and Administrative (G&A) expenses increased by $0.03 million.
- Capital Structure: Significant equity activity occurred in Q3 2024, including a "Warrant Inducement" that resulted in the issuance of 2.55 million shares and new Class E warrants, raising approximately $3.5 million in net proceeds. This activity helped satisfy the Nasdaq Stockholders' Equity Requirement.
- Legal Settlements: The company incurred significant non-recurring expenses related to legal judgments, including a $7.5 million settlement with LifeSci Capital LLC and costs related to a settlement with A-IR Clinical Research Ltd., contributing to the YTD loss.
Outlook, Risks, and Management Commentary
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. With $6.54 million in cash and no revenue, the company does not anticipate having sufficient funds to sustain operations for one year from the filing date. Additional financing is required.
- NASDAQ Compliance: The company received a delisting notice from Nasdaq regarding the Minimum Bid Price Requirement (stock price below $1.00). While the company satisfied the Stockholders' Equity Requirement through Q3 financing, it is not eligible for a standard compliance period due to a recent reverse stock split. An appeal hearing was requested on October 23, 2024.
- Legal Proceedings: The company settled a lawsuit with LifeSci Capital LLC for $7.5 million (paid in August 2024) and settled a claim with A-IR Clinical Research Ltd. These events resulted in significant one-time charges.
- Future Guidance: The company expects to continue incurring significant operating losses as it advances clinical trials for GEM-AKI, GEM-CKD, and GEM-PSI. No revenue is expected until regulatory approval is obtained, which is not anticipated for several years.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $6.54 million cash balance against projected burn rates and the timeline for securing additional capital.
- NASDAQ Status: Monitor the outcome of the appeal hearing regarding the Minimum Bid Price delisting notice and any potential reverse stock splits.
- Legal Exposure: Confirm that the $7.5 million LifeSci settlement and A-IR settlement are fully resolved with no further contingent liabilities.
- Dilution Risk: Assess the impact of the 5.1 million Class E warrants issued in the inducement and other outstanding warrants on future share count and dilution.
- Warrant Liability: Review the accounting treatment of warrant liabilities and the volatility of fair value adjustments on the income statement.